AstraZeneca’s (AZN) “Sell” Rating Reiterated at Deutsche Bank Aktiengesellschaft

by · The Markets Daily

Deutsche Bank Aktiengesellschaft reaffirmed their sell rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report released on Wednesday morning, MarketBeat.com reports. Deutsche Bank Aktiengesellschaft currently has a £115 price objective on the biopharmaceutical company’s stock.

AZN has been the topic of several other reports. Citigroup boosted their target price on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Monday, August 3rd. Finally, Berenberg Bank reiterated a “buy” rating and issued a £160 target price on shares of AstraZeneca in a report on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of £152.17.

Get Our Latest Analysis on AZN

AstraZeneca Trading Up 0.4%

Shares of AZN opened at £118.96 on Wednesday. The business’s 50-day moving average price is £131.96 and its 200 day moving average price is £139.44. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The stock has a market capitalization of £184.49 billion, a P/E ratio of 17.81, a P/E/G ratio of 0.86 and a beta of 0.23. AstraZeneca has a 1-year low of £107.84 and a 1-year high of £157.32.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Further Reading